TFCP2L1 Antibodies

Transcription factor CP2-like protein 1 (TFCP2L1)

Transcription factor that facilitates establishment and maintenance of pluripotency in embryonic stem cells (ESCs) (PubMed:25215486, PubMed:26906118). With KLF2, acts as the major effector of self-renewal that mediates induction of pluripotency downstream of LIF/STAT3 and Wnt/beta-catenin signaling (By similarity).

Required for normal duct improvement in the salivary gland and kidney (By similarity). Coordinates the development of the kidney collecting ducts intercalated (IC) and principal (PC) cells, which regulate acid-base and salt-water homeostasis, respectively (By similarity).

Gene Information

Human
Gene Name:	TFCP2L1
Uniprot:	Q9NZI6
Entrez:	29842

Family

Belongs to:
grh/CP2 family

Alternative Names

CRTR1; CRTR1CRTR-1; LBP9; LBP-9; LBP9CP2-related transcriptional repressor 1; TFCP2L1; transcription factor CP2-like 1; transcription factor CP2-like protein 1; Transcription factor LBP-9

Molecular Weight

Mass (kDA):
54.627 kDA

Genomic Context

Human
Location:	2q14.2
Sequence:	2; NC_000002.12 (121216587..121285210, complement)

Tissue Specificity

Highly expressed in placental JEG-3 cells and very low levels of expression in non-steroidogenic cells. No expression was seen in adrenal NCI-H295A cells or in adrenal tissue.

Subcellular Localizations

Nucleus.

Diseases

• Neoplasms
• Malignant Neoplasms
• Carcinoma
• Thyroid Neoplasm
• Neoplasm Metastasis
• Malignant Neoplasm Of Kidney
• Metastatic Malignant Neoplasm To The Lung
• Malignant Neoplasm Of Breast
• Neoplasm By Morphology
• Kidney Neoplasm
• Carcinoma, Papillary
• Braf Np_004324.2:p.v600e
• Goiter

• Renal Cell Carcinoma
• Cytoplasmic Accumulation
• Mammary Neoplasms
• Papillary Thyroid Carcinoma
• Anaplasia
• Lung Neoplasms
• Primary Neoplasm

Pathways

• Methylation
• Gene Silencing
• Cell Cycle
• Protein Folding
• Dedifferentiation
• Localization
• Transdifferentiation

• Protein Oligomerization

PTMs

• Cleavage

• Sumoylation

• Methylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/TFCP2L1

Best Uses Of The TFCP2L1 Marker

Steven Boster was a late 1990s product developer. He earned the nickname "he that converts science in a lavatory" during the late 1990s. He invented several IHC products, and hundreds of primary antibody products. He was China's largest anti-globalization company by the late 90s. PicoKine (tm), a proprietary ELISA system, was created by Boster. This proprietary ELISA platform allows the development of high-sensitivity ELISA kit.

TFCP2L1

Numerous biological assays use the TFCP2L1 gene marker to confirm the presence of a gene. These antibodies can either be monoclonal (or polyclonal) and were developed in rabbits and mice. This antibody was highly specific and has a high affinity to TFCP2L1 protein. Boster Bio is a trusted name in the research community because their antibodies are validated in Western Blotting, Immunohistochemistry, and ELISA.

TFCP2L1 antibodies

Boster Bio is a top source for high quality TFCP2L1 antibodies. TFCP2L1 antibodies are available in both monoclonal as well as polyclonal formats. Boster Bio's TFCP2L1 antibodies are developed using a rabbit and mouse model. Boster Bio products require a sample to be purchased.

By lysing cells in RIPA buffer, samples were prepared and analysed for protein concentrations using a BCA kit. Equal amounts of protein were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to PVDF membranes. The membranes were then blocked with 5% skimmed Milk. After blocking the membranes, primary antibodies were incubated with secondary antibodies and detected by chemiluminescence using the SuperSignal West Pico substrate.

The primary antibody was purchased from Boster Bio, Wuhan, China. Secondary antibodies were purchased from Abcam, Danvers MA, USA, Santa Cruz CA, and Active Motif. The primary antibody was used as an immunofluorescence dye to stain tissue sections. The cells were visualized by a confocal microscopy. Fig. 1. Boster Bio TFCP2L1 antibodies can be used in research to identify TFCP2L1 human cells.

TFCP2L1 in human umbilical chord mesenchymal stem cell TFCP2L1.

Researchers discovered that TFCP2L1 was expressed on the surfaces of human umbilical chord mesenchyal stem cell mesenchyal. These cells secrete inflammatory chemicals, inhibit the proliferation activated T lymphocytes and induce regulatory cells. These cells are potential candidates to be used in cell-based therapies. Recent studies have shown that UCMSCs inhibit the proliferation and migration of tumor cells and can increase the engraftment rates of hematopoietic-derived stem cells.

HUCMSCs have been shown induce leukemia cell apoptosis. This is due to the oxidative-stress pathway. HUC-MSCs increase SOD activity and decrease GSH–Px activity. HUC-MSCs can also increase levels BDNF (glial cell-derived nervetrophic factor) and GHNF, which are factors that enhance the survival, function, and survival of neurons. TFCP2L1 may be expressed in different types stem cells.

HUC-MSCs offer a promising treatment for a variety of diseases, including cardiovascular disease. The transplanted cells improve cardiac contractile functions, decrease infarct volume, and improve the ejection fraction. HGF and other chemotherapy cytokines are also secreted in the HUC–MSCs. This can help to reduce inflammation and cardiac fibrosis.

HUCMSCs may help relieve symptoms associated with spinal cord injuries. TFCP2L1 is also associated with neuronal regeneration. Moreover, HUC-MSCs inhibit the activity of the mitogen-activated protein kinase (MAPK) pathway, resulting in decreased apoptotic cell death in the spinal cord. HUC-MSCs might also decrease the formation glial scar tissue. These effects can only be understood by large-scale clinical research.

TFCP2L1 in human primordial germ cell-like cells

KLF4 & TFCP2L1 play a critical role in the establishment of naive like ground-state pluripoency in human primordial ger cells (hPGCLCs). These transcription factors don't play an important role for the induction PGCLC gene expression. This study sheds light on the function of these transcription factor in human primordial stem cells. This model also suggests that KLF4 and TFCP2L1 have divergent functions in human primordial germ cell-like cells.

The TFCP2L1 gene is essential for the development of embryonic stem cells. This gene regulates the specification in mice of human primordial germ cells. Researchers have identified a number of genes that regulate its expression. Dietmann F, Tang S, Bao SF, Diamanti EB, and Gottgens BB are some of these genes. However, the researchers are still working to determine the role of this gene in human embryonic stem cells.

The early post-implantation embryo is when mammals begin to identify primordial germ cells. This process involves a complex network of gene regulatory genes that includes WNT3b-catenin-signaling. This program also requires the SOX17 - BLIMP1 axis. The surface markers EpCAM and INTEGRINA6 are expressed by human PGCLCs. Non-rodent mammals, however, are still unaware of the signaling mechanism.

KLF4 (and TFCP2L1) are critical for hPGCLC specifications, but they don't need to be in the same order for naive pluripotency. KLF4 also plays a critical role in maintaining naive pluripotency in hPGCs. These genes can also be expressed to address the causes of germ cell cancers and infertility in people.

Stella and Dppa1 are important genes involved in the hPGCLC initiation process. Blimp1 suppresses early PGCs' somatic program and promotes germline-specific genes. Mutations in either of these genes lead to the loss of PGCs by E12.5, thereby preventing the induction of human germ cells.

Using a Zeiss Inverted Confocal Microscope, hPGCLCs were grown in a laboratory to study TFCP2L1 in human primordial germ cells-like cells. The cells were stained using an anti-KLF17 antibody (1.200).